Skip to main content
ICD-10-PCS/XW0/XW033A7
Inpatient Procedure Code

XW033A7

Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

Introduce Ciltacab in Periph Vein, Perc, New Tech 7

Axis Breakdown

Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.

PositionValueMeaning
1
SectionX

New Technology

2
Body SystemW

Anatomical Regions

3
Root Operation0

Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

4
Body Part3

Peripheral Vein

5
Approach3

Percutaneous

6
Device / Substance / TechnologyA

Ciltacabtagene Autoleucel

7
New Technology Group7

New Technology Group 7

Potential MS-DRG Relationships (FY2026)

The MS-DRG grouper treats this as a non-operating-room procedure. It appears in the surgical logic of 1 MS-DRG:

  • MDC PRE — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies: DRG 018

From the CMS MS-DRG Definitions Manual, Appendix E. Actual DRG assignment depends on the complete claim.

Contextual Map

Every relationship of XW033A7 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

PCS table

  • XW0[PCS table]
  • [object Object] — Section: [object Object] [Section]: “[object Object]”
  • [object Object] — Body System: [object Object] [Body System]: “[object Object]”
  • [object Object] — Operation: [object Object] [Operation]: “[object Object]”

MS-DRG participation

  • DRG 018 — CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES [MS-DRG]: “CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies (MDC PRE)”

MDC crossing · diagnoses (1333)

  • Pre-MDC[MDC crossing]: “Pre-MDC — the grouper's crossing between diagnoses and procedures: a principal diagnosis sets the MDC, and same-MDC procedures move the stay to its surgical DRGs.”
  • A36.0 — Pharyngeal diphtheria [Same-MDC diagnosis]: “Pharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A36.1 — Nasopharyngeal diphtheria [Same-MDC diagnosis]: “Nasopharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A36.2 — Laryngeal diphtheria [Same-MDC diagnosis]: “Laryngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A54.5 — Gonococcal pharyngitis [Same-MDC diagnosis]: “Gonococcal pharyngitis — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • A56.4 — Chlamydial infection of pharynx [Same-MDC diagnosis]: “Chlamydial infection of pharynx — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
  • and 1328 more

Nearest codes

  • XW03357 — Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW03367 — Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW03377 — Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW03387 — Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW033B7 — Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW033C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW033G7 — Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
  • XW033H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]

Change history

No changes recorded for this code — unchanged since the FY2026 (April) baseline of the change ledger.